Search

Your search keyword '"Mourey L"' showing total 485 results
Start Over Author "Mourey L"
485 results on '"Mourey L"'

151. Crystal structure of Amylosucrase inactive double mutant F290K-E328Q from Neisseria polysaccharea in complex with sucrose.

Author

Guerin, F., primary, Champion, E., additional, Moulis, C., additional, Barbe, S., additional, Tran, T.H., additional, Morel, S., additional, Descroix, K., additional, Monsan, P., additional, Mulard, L.A., additional, Remaud-Simeon, M., additional, Andre, I., additional, Mourey, L., additional, and Tranier, S., additional

Published
2012
Full Text
View/download PDF

152. Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)

Author

Gravis, G., primary, Fizazi, K., additional, Joly Lobbedez, F., additional, Oudard, S., additional, Priou, F., additional, Latorzeff, I., additional, Delva, R., additional, Krakowski, I., additional, Laguerre, B., additional, Rolland, F., additional, Théodore, C., additional, Deplanque, G., additional, Ferrero, J.M., additional, Pouessel, D., additional, Mourey, L., additional, Beuzeboc, P., additional, Zanetta, S., additional, Esterni, B., additional, Habibian, M., additional, and Soulie, M., additional

Published
2012
Full Text
View/download PDF

168. Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).

Author

Fizazi, K., primary, Lesaunier, F., additional, Delva, R., additional, Gravis, G., additional, Rolland, F., additional, Priou, F., additional, Ferrero, J., additional, Houede, N., additional, Mourey, L., additional, Theodore, C., additional, Krakowski, I., additional, Berdah, J. F., additional, Baciuchka, M., additional, Kerbrat, P., additional, Davin, J., additional, Berille, J., additional, Habibian, M., additional, Ichante, J., additional, Laplanche, A., additional, and Culine, S., additional

Published
2011
Full Text
View/download PDF

171. Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel—An analysis of final safety results.

Author

Oudard, S., primary, Latorzeff, I., additional, Beuzeboc, P., additional, Caty, A., additional, Sevin, E., additional, Delva, R., additional, Rolland, F., additional, Mourey, L., additional, Priou, F., additional, and Culine, S., additional

Published
2010
Full Text
View/download PDF

192. CRYSTAL STRUCTURE OF FIXJ-N

Author

Gouet, P., primary, Fabry, B., additional, Guillet, V., additional, Birck, C., additional, Mourey, L., additional, Kahn, D., additional, and Samama, J.P., additional

Published
1999
Full Text
View/download PDF

199. Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.

Author

Delord JP, Bennouna J, Mourey L, Bougaret J, Brandely-Talbot M, Ferré P, Delord, Jean-Pierre, Bennouna, Jaafar, Mourey, Loïc, Bougaret, Joël, Brandely-Talbot, Maud, and Ferré, Pierre

Abstract

Background: Vinflunine is a new-generation microtubule inhibitor, which is currently registered in Europe and in some countries elsewhere as an intravenous formulation for the second-line treatment of transitional urothelial cell carcinoma. On the basis of favourable non-clinical results, the clinical development of an oral formulation was initiated.Objective: The absolute oral bioavailability was investigated in patients through two consecutive trials: the first trial used soft gelatin capsules filled with solubilized vinflunine (SLCaps), while the second study investigated hard gelatin capsules containing vinflunine as a formulated powder (HPCaps).Study Design: Each pharmacokinetic trial was conducted according to a randomized cross-over design. Patients received 120 mg/m2 of either oral (SLCaps or HPCaps) or intravenous vinflunine on day 1, followed by the alternate dosing route after a 2-week washout period. Blood samples were collected over 168 hours. A pharmacokinetic analysis was conducted for each patient and route of dosing to derive the absolute oral bioavailability of SLCaps and HPCaps.Results: A total of 12 and 22 patients were enrolled, for SLCaps and HPCaps, respectively. Vinflunine absorption was rapid for both oral formulations. Blood concentrations peaked at 2.5 hours following oral intake with food, and then decreased similarly to the intravenous profile. The mean absolute bioavailability was high, at 58.3 ± 14.4% (SLCaps) and 57.3 ± 11% (HPCaps), with limited inter-individual variability (coefficient of variation = 25% and 19% for SLCaps and HPCaps, respectively). Neither sequence nor period effects were detected. The gastro-intestinal tolerance was satisfactory. The main drug-related adverse events were asthenia, fatigue, constipation and neutropenia, mostly of grade 1 or 2. No grade 4 and no drug-related serious adverse events were reported.Conclusion: The high bioavailability and low inter-individual variability are favourable pharmacokinetic properties, which could be valuable for further clinical development of oral vinflunine. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

200. 893O - Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)

Author

Gravis, G., Fizazi, K., Joly Lobbedez, F., Oudard, S., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., Rolland, F., Théodore, C., Deplanque, G., Ferrero, J.M., Pouessel, D., Mourey, L., Beuzeboc, P., Zanetta, S., Esterni, B., Habibian, M., and Soulie, M.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results